Recent advances in the new generation taxane anticancer agents

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Paclitaxel and docetaxel are vital anticancer drugs but face challenges with side effects and drug resistance.
• Development of novel taxane analogs is crucial for overcoming these limitations.
• Second-generation taxanes aim for enhanced pharmacological properties and activity against resistant cancers.

Purpose of the Study:

• To review advances in new generation taxane anticancer agents.
• To highlight structure-activity relationship (SAR) studies leading to novel taxanes.
• To discuss novel delivery systems and conjugates for improved cancer therapy.

Main Methods:

• Review of recent preclinical and clinical data on novel taxanes.
• Structure-activity relationship (SAR) studies for taxane analog design.
• Photoaffinity labeling and solid-state NMR for drug-binding domain and conformation studies.
• Development of taxane-monoclonal antibody (mAb) immunoconjugates and fatty acid conjugates.

Main Results:

• Ortataxel demonstrates potent activity against sensitive and resistant cancer cell lines and xenografts, with oral bioavailability.
• Studies identified drug-binding domains on tubulin and P-glycoprotein (Pgp).
• Novel taxane-mAb immunoconjugates and fatty acid conjugates show promising antitumor activity with reduced toxicity in preclinical models.

Conclusions:

• Second-generation taxanes, including Ortataxel, represent a significant advancement in cancer chemotherapy.
• Targeted delivery strategies like mAb immunoconjugates and fatty acid conjugation enhance efficacy and reduce toxicity.
• Further clinical development of these novel taxane agents is warranted.